This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Aeterna Zentaris (AEZS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of -450.00% and -99.12%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for AEterna (AEZS) This Earnings Season?
by Zacks Equity Research
AEterna (AEZS) may provide update on the path forward for Macrilen in Europe on the first-quarter earnings call.
Analysts Estimate Aeterna Zentaris (AEZS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Aeterna Zentaris (AEZS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aeterna Zentaris (AEZS) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Aeterna Zentaris (AEZS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What's in the Cards for Aeterna (AEZS) This Earnings Season?
by Zacks Equity Research
Aeterna (AEZS) growth hormone deficiency test, Macrilen, to drive revenues in the fourth quarter.
The Zacks Analyst Blog Highlights: Celgene, Charles River Laboratories International, Catalent and Aeterna Zentaris
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Charles River Laboratories International, Catalent and Aeterna Zentaris
4 Drug Stocks to Buy Despite Price Hearing Woes
by Nitish Marwah
A burgeoning economy has necessitated diversification by the top players in the industry. Given such positives, any decision to lower drug prices will not hamper the space.
The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna
by Zacks Equity Research
The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna
5 Tiny Biotech Stocks With Superb Growth Potential
by Swarup Gupta
A spurt in deal-making has boosted the sector this year which retains the ability to provide outsized gains.
Is AEterna Zentaris (AEZS) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (AEZS) Outperforming Other Medical Stocks This Year?
Implied Volatility Surging for Aeterna Zentaris (AEZS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Aeterna Zentaris (AEZS) stock based on the movements in the options market lately.
Amgen's Osteoporosis Candidate Evenity Gets Approval in Japan
by Zacks Equity Research
Amgen (AMGN) gets approval in Japan for osteoporosis candidate, Evenity.
Is AEterna Zentaris (AEZS) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (AEZS) Outperforming Other Medical Stocks This Year?
AEterna Zentaris Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
AEterna Zentaris has been struggling lately, but the selling pressure may be coming to an end soon.
Aeterna Zentaris (AEZS) Stock Moves -1.16%: What You Should Know
by Zacks Equity Research
In the latest trading session, Aeterna Zentaris (AEZS) closed at $2.56, marking a -1.16% move from the previous day.
Is AEterna Zentaris (AEZS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (AEZS) Outperforming Other Medical Stocks This Year?
Aeterna Zentaris (AEZS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Aeterna Zentaris (AEZS) closed at $2.90, marking a +1.75% move from the previous day.
Aeterna Zentaris (AEZS) Stock Moves -0.54%: What You Should Know
by Zacks Equity Research
Aeterna Zentaris (AEZS) closed at $3.67 in the latest trading session, marking a -0.54% move from the prior day.
Is AEterna Zentaris (AEZS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (AEZS) Outperforming Other Medical Stocks This Year?
Can The Uptrend Continue for Aeterna Zentaris (AEZS)?
by Zacks Equity Research
Investors certainly have to be happy with Aeterna Zentaris Inc. (AEZS) and its short term performance.
Mirati Therapeutics (MRTX) Soars: Stock Adds 13.6% in Session
by Zacks Equity Research
Mirati Therapeutics (MRTX) saw a big move last session, as its shares jumped nearly 14% on the day, amid huge volumes.
VIVUS (VVUS) in Focus: Stock Moves 5.6% Higher
by Zacks Equity Research
VIVUS (VVUS) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
MiMedx Group (MDXG) Soars: Stock Adds 11.2% in Session
by Zacks Equity Research
MiMedx Group (MDXG) shares rose more than 11% in the last trading session, amid huge volumes.
Inovio Pharmaceuticals (INO) in Focus: Stock Moves 5.7% Higher
by Zacks Equity Research
Inovio Pharmaceuticals (INO) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
Zacks.com highlights: Weight Watchers International, Aeterna Zentaris, TransUnion, Six Flags Entertainment and Johnson Outdoors
by Zacks Equity Research
Zacks.com highlights: Weight Watchers International, Aeterna Zentaris, TransUnion, Six Flags Entertainment and Johnson Outdoors